The EPS miss may pressure the stock near-term, but strong revenue growth and maintained guidance provide support. Watch for next quarter's revenue trajectory to see if sequential decline reverses and for pipeline updates (sNDA for infant atopic dermatitis, Phase 2 data in vitiligo/HS).
ARQT drugs
ARQT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $20.66entry
- T+1 · 6mo ago 0.00%α −0.83% · $20.66
- T+5 · 6mo ago +4.99%α +3.48% · $21.69
- T+20 · 6mo ago +3.34%α +0.20% · $21.35
- T+60 · 4mo ago +25.56%α +21.72% · $25.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arcutis Biotherapeutics reported Q1 2026 net product revenue of $105.4M (+65% YoY), beating consensus of $103.7M, but EPS of -$0.09 missed consensus of -$0.06. Full-year 2026 revenue guidance of $480M-$495M was maintained. The stock may face pressure from the EPS miss despite strong revenue growth and positive operating cash flow.
Key Financial Metrics
Key Facts
- Q1 2026 net product revenue $105.4M, +65% YoY vs $63.8M, beating $103.7M consensus
- GAAP EPS -$0.09 vs consensus -$0.06 (miss of 50%)
- Full-year 2026 revenue guidance maintained at $480M-$495M
- Positive operating cash flow of $2.2M in Q1 2026
- Sequential revenue declined 17% from Q4 2025 due to seasonality
- ZORYVE remains leading prescribed branded topical across three indications
- Completed dermatology sales force expansion; building primary care/pediatrics team
Financial Impact
Revenue beat by 1.6% ($1.7M), EPS missed by 50% (-$0.03 per share). Net loss improved to -$11.3M from -$25.1M YoY.
Risk Factors
- Sequential revenue decline due to seasonality may persist
- High SG&A expenses ($74.1M) burden profitability
- Dependence on ZORYVE for all revenue; pipeline candidates early-stage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289285 |
Track record
34 reports on ARQT
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
- Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers